Vitamin K antagonist (VKA)

DRUG8 trials

Sponsors

Sanofi, Bayer, Janssen Scientific Affairs, LLC, Bristol-Myers Squibb, Pfizer

Conditions

Atrial FibrillationDeep Vein ThrombosisNonvalvular Atrial FibrillationPercutaneous Coronary InterventionThrombosisTranscatheter Aortic Valve ReplacementTreatment of Venous Thromboembolism in Cancer Patients

Phase 2

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

CompletedNCT02981472

Bristol-Myers SquibbThrombosis

Start: 2017-01-19End: 2021-10-18Updated: 2022-10-03

Phase 3

Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

CompletedNCT00067093

SanofiDeep Vein Thrombosis

Start: 2003-05-31End: 2005-09-30Updated: 2011-04-06

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

CompletedNCT01674647

BayerAtrial Fibrillation

Start: 2012-10-31End: 2014-01-31Updated: 2015-04-30

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

CompletedNCT01830543

Janssen Scientific Affairs, LLCAtrial Fibrillation, Percutaneous Coronary Intervention

Start: 2013-05-10End: 2016-07-28Updated: 2017-09-19

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

TerminatedNCT02556203

BayerTranscatheter Aortic Valve Replacement

Start: 2015-12-16End: 2018-11-27Updated: 2020-01-13

Unknown Phase

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

CompletedNCT03374540

BayerNonvalvular Atrial Fibrillation

Start: 2017-12-01End: 2019-08-30Updated: 2020-08-17

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Active, not recruitingNCT05038228

PfizerAtrial Fibrillation

Start: 2022-08-01End: 2026-04-08Updated: 2026-03-12

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

CompletedNCT05150938

BayerTreatment of Venous Thromboembolism in Cancer Patients

Start: 2022-03-18End: 2023-02-28Updated: 2023-12-18

Related Papers

Pharmacometric analyses supporting apixaban doses in neonates with venous thromboembolism

Blood2025-11-03

Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.

2024-05-121 citations

Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease

Journal of the American College of Cardiology2023-12-0136 citations

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

CPT Pharmacometrics & Systems Pharmacology2023-03-029 citations

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism

JACC CardioOncology2023-02-0714 citations

Two‐year clinical outcomes after successful transcatheter aortic valve implantation with balloon‐expandable versus self‐expanding valves: A subanalysis of the GALILEO trial

Catheterization and Cardiovascular Interventions2022-08-306 citations

Addendum to British Society for Haematology guideline on the investigation, management and prevention of venous thrombosis in children (<i>Br. J. Haematol</i>. 2011; 154: 196–207)

British Journal of Haematology2021-08-308 citations

Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis.

2020-01-0135 citations

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

New England Journal of Medicine2019-11-16525 citations

Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation

Circulation Cardiovascular Interventions2019-11-013 citations

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2019-02-0111 citations

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

2018-10-0110 citations

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.

2018-03-1424 citations

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Circulation2016-11-1595 citations

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

New England Journal of Medicine2016-11-141525 citations

Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.

2016-10-3170 citations

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).

2014-12-20102 citations

Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation

European Heart Journal2014-09-02365 citations

Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q).

2009-04-0751 citations

Idraparinux versus standard therapy for venous thromboembolic disease.

2007-09-01215 citations